RSN Fundraising Banner
FB Share
Email This Page
add comment

Excerpt: "The FDA's decision not to reveal its advisors' relationships with the drugs' manufacturers and Bayer raises serious questions about the agency's treatment of potential conflicts of interest, a historically problematic area for the department."

A Bayer-Schering employee examines YAZ birth control pills in the company's factory in Berlin, 10/27/11. (photo: Bayer HealthCare AG)
A Bayer-Schering employee examines YAZ birth control pills in the company's factory in Berlin, 10/27/11. (photo: Bayer HealthCare AG)

FDA Panel Judging Birth Control Risk Had Ties to Bayer

By Jeanne Lenzer and Keith Epstein, Washington Monthly

14 January 12


The Yaz Men: Members of FDA panel reviewing the risks of popular Bayer contraceptive had industry ties

ast month, the U.S. Food and Drug Administration convened a committee of medical experts to weigh new evidence concerning the potential dangers of drospirenone, a synthetic hormone contained in popular birth control pills including Bayer AG's Yaz and Yasmin. In a decision that helped ensure the continued presence of these drugs on American pharmacy shelves, the committee concluded by a four-vote margin that the benefits of drugs with drospirenone outweigh the risks. However, an investigation by the Washington Monthly and the British medical journal BMJ has found that at least four members of the committee have either done work for the drugs' manufacturers or licensees or received research funding from them. The FDA made none of those financial ties public.

Yaz and Yasmin are among Bayer's top selling pharmaceutical products. According to the German drug manufacturer, over 4 million women worldwide use Yasmin alone. But the drug has also sparked growing controversy in recent months. A series of studies published in BMJ have shown that users of pills containing drospirenone have an increased risk of blood clots, which can cause deep vein thrombosis, pulmonary embolism, stroke, heart attack and death. And thousands of women have filed a lawsuit against Bayer, saying they were injured by Yaz or Yasmin.

Other Bayer products containing the hormone drospirenone are Beyaz and Safyral. In addition, four companies - Bayer, Teva, Watson and Sandoz - sell five generic versions of the drugs evaluated by the committee last month.

The FDA's decision not to reveal its advisors' relationships with the drugs' manufacturers and Bayer raises serious questions about the agency's treatment of potential conflicts of interest, a historically problematic area for the department. In 2004, controversy erupted over another FDA advisory hearing - involving the painkiller Vioxx - when it became clear that advisors with financial conflicts of interest were more likely than those without conflicts to vote that Vioxx was safe and should be allowed to stay on the market. The drug was ultimately withdrawn after a study showed it was associated with approximately 60,000 deaths. In 2008, partly in response to this uproar, the agency issued a new guidance on how to handle conflicts of interest among its advisors, stating that it wanted to reduce "bias" and to be more "transparent."

The agency's handling of the drospirenone hearings casts major doubt on how far it has gone to attain those goals.

What's more, interviews and records also show that the drospirenone advisory committee, when it voted last month, lacked significant information about increased risks to the health of women using contraceptives containing drospirenone.

The FDA ordered the safety review of drugs containing the hormone after three articles published in the BMJ found an increased incidence of blood clots among users of the pills. The advisors were given these studies prior to the December 8 meeting. However, the panel was not shown documents from a report by David Kessler, a former FDA commissioner and an expert witness in the lawsuit filed against Bayer on behalf the women who say they were injured by Yaz and Yasmin. Kessler's report cites internal Bayer corporate documents that suggest the company had withheld safety data from the FDA.

The documents show that in 2004, Bayer scientists reported in a draft analysis that Yasmin incurs av "several-fold increase" in reporting rates for blood clots compared to three other oral contraceptives, and that Yasmin's rate of all serious adverse events was "10 fold higher" than that of other products.

In his report, Kessler writes that Bayer failed to report safety data to the FDA, engaged in off-label promotion of the pills, and paid $450,000 to a high profile gynecologist to sponsor her book tour in which she promoted such off-label uses.

Kessler's report, originally under seal, was not released until December 6, two days prior to the advisory meeting. The FDA said it could not give the advisors the information because the date to submit documents had passed.

The FDA relies on some 50 advisory committees to obtain "independent" expert advice and "maintain the public trust." Recommendations on evidence for safety and efficacy can lead to drug approvals and withdrawals; while nonbinding, recommendations by such committees can move stock prices and are generally regarded as indicators of official FDA action.

Under FDA guidelines, when advisory committee members have a financial relationship with a drug company whose product is under review, the agency can issue waivers that acknowledge the advisors' links to industry but allow them to vote if their expertise is needed and no other specialists are available. Such waivers often serve as the only public signal that advisors have financial conflicts of interest. In the hearings on drospirenone, the FDA issued none.

And yet, according to public records, recently unsealed court documents, and interviews with some of the FDA advisors, at least four of the advisory committee members in this case have served as paid researchers, consultants, "key opinion leaders," or speakers for Bayer or other manufacturers or licensees of drospirenone. A fifth advisor agreed to serve as a consultant but never executed the agreement. A sixth received consulting fees from a law firm representing Bayer.

In a 15-to-11 vote, the committee decided that the benefits of drospirenone outweighed its risks.Had those members with undisclosed conflicts of interest voted the other way, the committee would have come to the opposite conclusion. The committee also voted 21 to 5 to change the drug labels to warn that the hormone can cause blood clots. But the panel stopped short of recommending that the labels should warn that they are more likely than other contraceptive pills to cause blood clots. Instead the experts suggested that the labels say that the evidence about blood clots is "conflicting."

Ironically, while the FDA allowed voting by advisors with business connections to drospirenone, the agency did bar another advisor - Sidney M. Wolfe, the panel's lone consumer advocate - on the grounds that he has an "intellectual conflict of interest." Wolfe, a former researcher, is a frequent critic of FDA practices on behalf of the advocacy group Public Citizen. Wolfe, the author of the consumer guide Good Pills, Bad Pills, had marked Yaz with a "do not take" advisory to readers. Jerome Hoffman, professor emeritus of medicine at UCLA, questioned Wolfe's exclusion from the panel: "The idea that because he has an opinion on data that already exist he should be prevented from voting is nutty."

Each of the advisors with ties to manufacturers told the Washington Monthly and BMJ that they fully disclosed their ties to the FDA, and there are no indications that the advisors failed to make required disclosures to the agency. The FDA, however, has declined to make public advisors' financial conflict of interest forms, explaining that the forms are "confidential" and no information from them can be shared under a section of the Ethics in Government Act.

When asked whether the agency was aware of any financial ties between its advisors and manufacturers or distributors of drospirenone, FDA spokeswoman Morgan Liscinsky said, "No waivers were issued."

But the committee's financial ties to Bayer begin with no less than its acting chair. Julia Johnson, a professor of obstetrics and gynecology at the University of Massachusetts Medical School, conducted four clinical trials - including one of drospirenone as hormone replacemen - for Bayer or its subsidiary Berlex, a manufacturer of drospirenone. She said in an e-mail, "The FDA is very vigilant on examining potential conflicts of interest and was aware of all my research." When asked for an interview, she said, "The U.S. FDA states that I cannot speak about the meeting."

Another advisor with ties to industry is Paula Hillard, a professor of obstetrics and gynecology at Stanford School of Medicine who has served as a paid consultant to Bayer Schering. Dr Hillard said she had fully complied with all FDA disclosures and referred the Washington Monthly and BMJ to the FDA for further questions. The FDA declined to respond to any questions, again citing the confidentiality clause of the Ethics in Government Act.

Elizabeth Raymond, a senior medical associate at Gynuity Health Projects in New York and another member of the committee, conducted studies funded by Barr, which has a licensing agreement with Bayer for generic versions of Yaz. Dr Raymond said that the FDA was "fully aware of all of my relevant current and past activities."

Anne E. Burke, an assistant professor of gynecology and obstetrics at Johns Hopkins University in Baltimore, has received research funding from Bayer-Berlex and Duramed, which has a licensing agreement with Bayer for generic Yaz and Yasmin. Dr Burke said that she fully disclosed this to the agency.

According to Dr Kessler's report, an internal Bayer document indicated that a fifth advisor received payment from Bayer, but that advisor told the Washington Monthly and BMJ that although she initially agreed to serve as a consultant for Bayer, the company never pursued the agreement. She said FDA records indicated that she had ties to Bayer due to her disclosure about her agreement, but after she was nominated to be on the drospirenone advisory committee, she corrected the error.

A sixth advisor, meanwhile, confirmed that he received consulting fees from a law firm representing Bayer in 2006. He told BMJ and the Washington Monthly that he did not disclose the information to the FDA because the FDA "did not require information for that time frame for consulting unrelated to the meeting topic."

Bayer spokesperson, Rosemarie Yancosek, said in an e-mailed statement: "Bayer had no input on who serves on the U.S. FDA Advisory Committee panel as the FDA has its own process for selecting panel members. Furthermore, it is Bayer's understanding that the FDA has a procedure for determining conflicts of interest for potential panel members."

The FDA does indeed have such a procedure, but critics argue that its guidelines define conflicts of interest too narrowly and provide too much flexibility in how they are applied. The guidelines are technically "suggested or recommended, but not required" provisions ( Whether an advisor can participate depends on "whether the discussion at the meeting or outcomes of the meeting will have a direct and predictable effect on the individual's interest." For instance, someone who was previously involved in another role for a manufacturer, or whose university received money from a manufacturer, may be allowed to participate. Even having a contract for $100,000 over a five-year period would not necessarily exclude an advisor, according to the guidelines.

Despite the FDA's frequent claims that there aren't enough experts independent of industry, a list of over 100 industry-independent experts has been presented to the agency - yet none of those experts has been tapped as an advisor.

The Project on Government Oversight, a Washington-based nonpartisan watchdog group, plans to raise concerns about the FDA's conflict of interest policies in a letter to the agency's top official, Margaret Hamburg.

"It shouldn't require a lawsuit and investigative journalism to learn about these kinds of conflicts," said the group's executive director, Danielle Brian. "The Yaz case puts FDA's feckless ethics policy into stark relief. It also reveals the human impact of conflicts of interest and why we need an FDA that shuns even the appearance of such conflicts."

The organization intends to urge the FDA to routinely disclose industry ties and more aggressively determine whether an advisor has a conflict. "Right now," said Brian, "the bar for considering whether an advisor has a conflict is too high." your social media marketing partner


A note of caution regarding our comment sections:

For months a stream of media reports have warned of coordinated propaganda efforts targeting political websites based in the U.S., particularly in the run-up to the 2016 presidential election.

We too were alarmed at the patterns we were, and still are, seeing. It is clear that the provocateurs are far more savvy, disciplined, and purposeful than anything we have ever experienced before.

It is also clear that we still have elements of the same activity in our article discussion forums at this time.

We have hosted and encouraged reader expression since the turn of the century. The comments of our readers are the most vibrant, best-used interactive feature at Reader Supported News. Accordingly, we are strongly resistant to interrupting those services.

It is, however, important to note that in all likelihood hardened operatives are attempting to shape the dialog our community seeks to engage in.

Adapt and overcome.

Marc Ash
Founder, Reader Supported News

-5 # 2012-01-15 05:36
This is a good article but publishing information on conflicts of interest does not solve the problem.

As long as the FDA has the power to keep drugs off the market, the conflicts have the potential of keeping beneficial drugs from needy patients and allowing risky drugs to be wantonly used on patients.

The FDA has a long history of regulatory delay which has been shown to cause the unnecessary deaths of tens of thousands of Americans -- the four year delay in allowing beta blockers on the market alone cost 40,000 American lives.

The best reform would be to make FDA findings advisory and to allow ill patients with the help of their doctors to make informed decisions about which risks are worth taking.

Lee Nason
New Bedford, Massachusetts
+1 # Glen 2012-01-16 16:25
Regulatory delay, Inason, has more to do with economics and control, than careful research. Big pharma has manipulated both the FDA as well as physicians and the government. Ever check into the medications that were offered that have proven to be hideously detrimental? How about the medications withheld that other countries offered that are excellent medications? All for control and economic motives.
+7 # jlohman 2012-01-15 06:58
Of course. When Vioxx was developed 9 of the 15 doctors sitting on the approval panel had financial ties to the company. Politicians did too because they took campaign bribes from the industry. And THEY set the rules!
+2 # lilpat126 2012-01-15 13:39
Bayer biggest rip off is aspirin. They have made claims since I can remember that their aspirin is superior to all others. They are all the same. Bayer just charges an outrageous price for theirs. They charge something like $6.00 for 60 low dose aspirin. I got 800 of the same thing at Sam's club for about $4.00. And they were making a good profit on the deal.
Big Pharma is ripping up off royally.
0 # Valleyboy 2012-03-06 10:24
Not many people know that Bayer was a major part of the huge chemical conglomerate Faben IG that enabled the holocaust.
They contributed to Hitler's campaign to get to power.
They ran the slave labour camp at Auschwitz.
They produced Zyklon B, the gas for the extermination chambers.
They were paid to select subjects for Mengele.

So putting a dangerous drug to market by any means possible regardless of the human cost would be right up Bayer's alley doncha think?

THE NEW STREAMLINED RSN LOGIN PROCESS: Register once, then login and you are ready to comment. All you need is a Username and a Password of your choosing and you are free to comment whenever you like! Welcome to the Reader Supported News community.